The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Fistula First Initiative: Advantages and Pitfalls
Abstract
History and Necessity for Fistula First Vascular Access Care before 1997 The arteriovenous fistula (AVF) was first described and used as a reliable form of hemodialysis (HD) vascular access (VA) by Brescia et al. (1) in 1966. Improvements in dialysis technology and the expansion of dialysis eligibility (e.g., inclusion of patients with diabetes) resulted in a rapid growth of the ESRD population. Many of these patients benefited from the development of prosthetic grafts when autogenous AVF were not feasible (2–5). In the mid-1980s, permanent catheters (central venous catheters [CVC]) in the internal jugular vein became a means of prolonging temporary access (6–8) and dramatically increased in use. The cumulative effect was a reduction in AVF use and an increase in graft and CVC use in the 1990s. This was associated with increased patient care costs; for example, up to 73% of patients were hospitalized to initiate dialysis and almost invariably had a temporary CVC inserted. VA was a major cause of morbidity and mortality (9), with HD access failure accounting for the most frequent cause of hospitalizations (10) and complications accounting for 14% of all ESRD expenses ($1 billion annually) (9). 1997 to 2003: Critical Events That Affected VA Care In an effort to improve VA outcomes, the National Kidney Foundation published the Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines for Vascular Access in 1997. The goal was to optimize management of VA through a set of evidence- and opinion-based based guidelines (10). In the following year, Centers for Medicare and Medicaid Services (CMS; the government-reimbursement agency for Medicare-insured patients) developed ESRD clinical performance measures (CPM) based on the K/DOQI VA guidelines, in response to the Balanced Budget Act of 1997 (11). VA-related CPM include (1) the proportion of HD patients with AVF, (2) the proportion of HD patients with a CVC, and (3) monitoring arteriovenous grafts for stenosis. The overriding goal of the CPM was to improve patient care and reduce costs. In 2002, the total Medicare costs for the ESRD program were $17 billion, an increase of 11% over costs in 2001 (11); VA procedures increased by four times since 1991 and approached $200 million (12). Nephrologists in the United States had to care for 340,000 patients who were receiving dialysis in more than 4500 facilities. Fistula First: A Landmark Initiative to Improve VA Care In 2003, the CMS and the ESRD networks jointly formed and implemented a National Vascular Access Improvement Initiative called the Fistula First Initiative (FFI) (13). The primary goal of this continuous quality improvement (CQI) project was to increase the appropriate use of AVF for HD access and to reach or exceed the K/DOQI guidelines of 50% in incident and 40% in prevalent patients (14). The recently revised goal is to have 65% of prevalent patients using an AVF by 2009 (13). The basis of the FFI, the CQI process, is important to review. The PDSA model of improvement is based on four basic elements: Plan–Do–Study–Act (Figure 1). The cycle begins with an improvement plan and ends with actions based on the learning gained from the Plan, Do, and Study phases. The FFI Workgroup determined the Plan, and the ESRD networks diligently implemented the plan in the Do phase. The Study, or analysis, phase not only evaluates whether the change was an improvement but also acknowledges, synthesizes, and considers new knowledge gained. The results of this evaluation will determine changes to be made in the Act phase, completing the cycle. The FFI Workgroup has already acted by increasing the target for prevalent AVF (from 40 to 65%), seemingly without complete consideration of the findings in the study phase, because the total impact of increasing AVF to the original 40% target is unclear. AVF have been promoted as the “best form of HD VA” on the basis of their superior patency, low complication and procedure rates, and subsequent low overall cost. Recall that the data on which the FFI and K/DOQI guidelines were based are now more than a decade old. Are these premises still valid in the 2007 Fistula First environment? The purpose of this article is to review the intended and unintended consequences of the FFI and to highlight the need for continual reevaluation by examining the impact of FFI on other ESRD care indicators and its effect on systemwide health care and specific patient costs, hospitalizations, and complications. Impact of the FFI The FFI should be applauded for its enthusiasm, resources provided, and positive impact on many programs. For example, the 2005 CPM Annual Report demonstrated that 39% of prevalent patients from a select sample were using an AVF during their last HD session (October through December 2004) (15). Individual programs have demonstrated even more impressive increases in AVF placement and use (Table 1). FFI provided motivation and support in the form of educational
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic Hemodialysis Using Venipuncture and a Surgically Created Arteriovenous Fistula
Brescia, M. J., Cimino, J. E., Appel, K., & Hurwich, B. J. (1966) · New England Journal of Medicine · doi:10.1056/nejm196611172752002 · Cited by 1,717
Clinical Practice Guidelines for Vascular Access
(2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.04.040 · Cited by 1,593
Vascular access use in Europe and the United States: Results from the DOPPS
Pisoni, R. L., Young, E. W., Dykstra, D. M., Greenwood, R. N., Hecking, E., Gillespie, B., Wolfe, R. A., Goodkin, D. A., & Held, P. J. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00117.x · Cited by 851
Type of vascular access and mortality in U.S. hemodialysis patients
Dhingra, R. K., Young, E. W., Hulbert-Shearon, T. E., Leavey, S. F., & Port, F. K. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00947.x · Cited by 769
Increasing arteriovenous fistulas in hemodialysis patients: Problems and solutions
Allon, M., & Robbin, M. L. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00551.x · Cited by 763
Sarnak, M. J. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00337.x · Cited by 723
Hemodialysis vascular access morbidity.
Feldman, H. I., Kobrin, S., & Wasserstein, A. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v74523 · Cited by 667
Silva, Jr., Hobson II, R. W., Pappas, P. J., Jamil, Z., Araki, C. T., Goldberg, M. C., Gwertzman, G., & Padberg, Jr. (1998) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(98)70360-x · Cited by 631
Hemodialysis Vascular Access Dysfunction: A Cellular and Molecular Viewpoint
Roy-Chaudhury, P., Sukhatme, V. P., & Cheung, A. K. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005050615 · Cited by 584
Vascular Access for Hemodialysis Patency Rates and Results of Revision
PALDER, S. B., KIRKMAN, R. L., WHITTEMORE, A. D., HAKIM, R. M., LAZARUS, J. M., & TILNEY, N. L. (1985) · Annals of Surgery · doi:10.1097/00000658-198508000-00015 · Cited by 514
Cited by
KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update
Lok, C. E., Huber, T. S., Lee, T., Shenoy, S., Yevzlin, A. S., Abreo, K., Allon, M., Asif, A., Astor, B. C., Glickman, M. H., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.12.001 · Cited by 2,590
Self-citationSidawy, A. N., Spergel, L. M., Besarab, A., Allon, M., Jennings, W. C., Padberg, F. T., Murad, M. H., Montori, V. M., O'Hare, A. M., Calligaro, K. D., et al. (2008) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2008.08.042 · Cited by 553
Patients’ Perspectives on Hemodialysis Vascular Access: A Systematic Review of Qualitative Studies
Casey, J. R., Hanson, C. S., Winkelmayer, W. C., Craig, J. C., Palmer, S., Strippoli, G. F. M., & Tong, A. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.06.024 · Cited by 159
Metadata
- Authors
- Lok, C. E.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2007-09
- Volume
- 2
- Issue
- 5
- Pages
- 1043-1053
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2131265195
- Cited by
- 338
- References
- 60
- FWCI
- 10.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fistula First Initiative: Advantages and Pitfalls. https://app.cochat.ai/papers/10.2215/cjn.01080307
- The paper
- Lok, C. E. (2007). Fistula First Initiative: Advantages and Pitfalls. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.01080307
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.